LEADERSHIP R & D CLINICAL DEVELOPMENT PATIENTS INVESTORS NEWSROOM CAREERS CONTACT US HOME WELCOME Revolutionizing Regenerative Medicine BioMimetic Therapeutics, Inc. is an emerging leader in the development and commercialization of drug-device combination products for the repair of orthopedic injuries to bone, cartilage, ligaments and tendons. BioMimetic's suite of products and product candidates combine recombinant protein therapeutics with tissue specific scaffolds, actively stimulating tissue healing and regeneration. BioMimetic believes its biologically-enhanced orthopedic therapies can improve the treatment options and quality of life for millions of patients suffering injuries or deterioration of the bones, cartilage (joints), ligaments and tendons.   Recent BioMimetic Therapeutics Announcements BioMimetic Therapeutics Launches AugmentTM as the New Brand Name for the Company's Orthopedic Product Line; Clinical Investigator to Present Canadian Trial Results at AOFAS Meeting   BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Jefferies 2nd Annual Healthcare Conference   BioMimetic Therapeutics Announces Highlights from Annual Meeting of Stockholders   BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Bank of America Securities 2008 Healthcare Conference   BioMimetic Therapeutics Releases First Quarter Earnings Results; $33.4 Million Cash Received from the Sale of Orofacial Therapeutic Business   BioMimetic Therapeutics to Report 2008 First Quarter Financial Results on May 8   BioMimetic Therapeutics Receives Written Communication from FDA Confirming Status of Ongoing Pivotal Trial for GEM OS1; No Changes Recommended to Trial Design     BioMimetic Therapeutics, Inc. For more information, please e-mail us. Website development and managed hosting by Acuity Marketing Communications, Inc.